APA (7th ed.) Citation

Baek, G. H., Kim, B. R., Kim, B. R., Shin, J., Huh, C. H., Hwang, J., . . . Na, J. A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: A proof-of-concept study with Post-hoc biomarker analysis. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Baek, Gyeong Ho, et al. A Phase 2a Double-blind, Placebo-controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-concept Study with Post-hoc Biomarker Analysis. Frontiers Media S.A.

MLA (9th ed.) Citation

Baek, Gyeong Ho, et al. A Phase 2a Double-blind, Placebo-controlled, Randomized Clinical Trial Evaluating the Efficacy and Safety of NuGel, a Novel Topical GPCR19-mediated Inflammasome Inhibitor, in Patients with Mild to Moderate Atopic Dermatitis: A Proof-of-concept Study with Post-hoc Biomarker Analysis. Frontiers Media S.A.